Strategic partnerships Graftys has a history of strategic acquisitions and distribution partnerships, including the 2021 acquisition of Biologics4life and a December 2019 private label partnership with OrthoPediatrics. This suggests sales opportunities through expanded distribution channels and joint commercialization of new bone regeneration products.

Global expansion Products are marketed in more than 25 countries across Europe and the United States. Target markets for growth include additional U.S. regions, Europe-wide partnerships, and entry into countries with high orthopedic and dental biomaterials demand.

Regenerative focus The company specializes in resorbable calcium-phosphate bone cements and regenerative biomaterials. This domain aligns with surgeons and hospitals seeking advanced graft substitutes and could pair with device providers or larger medtech distributors to accelerate adoption.

Small but targeted With 11-50 employees and revenue under $1M, Graftys represents a niche, high-value opportunity for strategic buyers, contract manufacturers, and OEM partners who can scale commercialization and leverage Graftys’ patented materials in larger product lines.

Financial leverage Having secured $13M in funding, the company has capital for clinical validation, regulatory filings, and expanded manufacturing. This offers opportunities for co-investment deals, leveraged pilots, and longer-term contracts with favorable terms for growth-oriented partners.